Recruiting

Testing a new medication to prevent tuberculosis in high-risk people

Plain-English translation of NCT06568484 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether — a newer tuberculosis medication — can safely prevent tuberculosis disease from developing in people who have been exposed to someone with tuberculosis or who are living with HIV. Researchers want to see if this medication works as well as or better than the treatments doctors currently recommend for preventing tuberculosis in these high-risk groups.

Tuberculosis is a serious infection that spreads through the air, and people who are exposed to it or who have HIV are at high risk of developing the disease. Current prevention treatments take months and have side effects; this trial is testing whether the new treatment could work faster and be easier for patients to take.

Do you qualify?

You likely qualify if…

you have been in close contact with someone who has been diagnosed with tuberculosis within the past 90 days
you are a child under 5 years old who has been exposed to tuberculosis, regardless of other health factors
you are 5 years or older and either tested positive for tuberculosis infection or are living with HIV
you are living with HIV and are taking specific HIV medications that do not interact with the study drug
you or your parent/guardian are able and willing to provide informed consent to participate

You likely don't qualify if…

you have already developed active tuberculosis disease
you are taking HIV medications that would dangerously interact with the study medication
you are pregnant and cannot safely switch to a compatible HIV medication regimen
you cannot commit to the study visits and medication schedule

What participation looks like

You would take the study medication daily for either 4 weeks or 6 months, depending on which group you are in and your tuberculosis exposure type. You would attend clinic visits for check-ins, blood tests, and monitoring to make sure the medication is working safely. The study is enrolling people across areas with high tuberculosis rates.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(6 sites)

Peru

HNSEB (Hospital Nacional Sergio E. Bernales), Lima

SES Policlinico, Lima

Tanzania

Kilimanjaro Clinical Research Institute, Moshi

Uganda

Joint Clinical Research Centre, Kampala

Makerere Lung Institute, Kampala